Healthy result as Dibbs acts on ASX float

Dibbsbarker has acted on the listing of a biotechnology company on the ASX.

Digital • 05 November 2013 • Big Law

Firms:Dibbsbarker (Regeneus Ltd)

You’re out of free articles for this month

Username or Email

Password Forgot password?

Keep me signed in on this device.

First Name

Last Name

Mobile

Organisation Type

By becoming a member, I agree to receive information and promotional messages from Lawyers Weekly. I can opt out of these communications at any time. For more information, please visit our Privacy Statement.

Need help signing up? Visit the Help Centre.

Deal: Biotechnology company Regeneus’ listing on the Australian Stock Exchange (ASX)

Area: Equity Capital Markets

Value: The company’s IPO raised $10.5 million at $0.25 per share, which valued the company at $45.9 million upon listing

Key players: The DibbsBarker team was led by commercial partners Geoff Cairns and Lis Boyce (pictured)

VIEW ALL

Deal significance:This is the first listing of a biotechnology company on the ASX since 2011 Regeneus, which was founded in 2007, isa Sydney-based regenerative medicine company. The funds raised by the IPO will bolster the company’s research and development efforts and assist in the commercialisation of new technologies and therapies.

You need to be a member to post comments. Become a member for free today!

Lawyers Weekly - legal news for Australian lawyers

SECTIONS

MORE

Healthy result as Dibbs acts on ASX float

OUR PLATFORMS AND BRANDS

EVENTS AND SUMMITS

PODCASTS

LEARNING AND EDUCATION

MOMENTUM MARKETS NETWORK

LINKS

STAY CONNECTED